Global Montelukast Sodium Market Report 2024: A USD 2.24 Billion Market by 2034 at a CAGR of 15.7%, Driven by Rising Prevalence of Respiratory Diseases and Enhanced Drug Formulations
28 mars 2024 08h20 HE
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Montelukast Sodium Market" report has been added to ResearchAndMarkets.com's offering.The global montelukast sodium market size was estimated...
United States Asthma Market Report - Insights into Primary HCP Interaction, Treatment Awareness, Satisfaction, Control and Clinical Trial Interest
12 mars 2024 13h56 HE
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Asthma in America 2023: Key Insights into Treatment Awareness & Satisfaction" report has been added to ResearchAndMarkets.com's offering. More...
IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer’s Disease
10 juil. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 10, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will present a Montelukast...
IntelGenx Announces Addition of Peterborough’s Kawartha Centre as Montelukast VersaFilm® Phase 2a Clinical Trial Site
19 juin 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, June 19, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, the Kawartha Centre has...
IntelGenx Announces Addition of Ottawa Montelukast VersaFilm® Phase 2a Clinical Trial Site; First Patient in Study Completes 26-Week Treatment
10 juin 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, June 10, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it has added a new Ottawa site...
IntelGenx Presents at 14th International Conference on Alzheimer’s and Parkinson’s Disease
04 avr. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 04, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced its two Montelukast poster...
IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results
22 mars 2019 16h05 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 22, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter...
IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site
14 févr. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that, subject to final research...
IntelGenx Provides Update on Phase 2a Montelukast VersaFilm™ Clinical Trial
23 janv. 2019 08h00 HE
|
IntelGenx Technologies Corp.
Eight Alzheimer’s Disease Patients Randomized to Date with Two Additional Sites Expected SAINT LAURENT, Quebec, Jan. 23, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT)...
IntelGenx Begins Montelukast VersaFilm™ Dosing in Patients with Mild to Moderate Alzheimer’s Disease in Phase 2a Study
27 nov. 2018 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 27, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient dosing has commenced in the Phase 2a...